{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T13:48:30Z","timestamp":1716644910058},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75\u00a0years old. However, patients aged \u2265\u200975\u00a0years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the efficacy and safety of glecaprevir and pibrentasvir (G\/P) treatment in Japanese patients with HCV infection aged \u2265\u200975\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multicenter, retrospective study included 271 Japanese patients with HCV infection from 12 centers in Miyazaki Prefecture, Japan. Demographic, clinical, virological, and adverse events (AEs) data obtained during and after G\/P treatment were collected from medical records. The patients were divided into two groups: younger (n\u2009=\u2009199, aged &lt;\u200975\u00a0years) and older (n\u2009=\u200972, aged \u2265\u200975\u00a0years). Virological data and AEs were analyzed according to the age group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In intention-to-treat (ITT) and per-protocol analyses, the overall sustained virological response 12 (SVR12) rates were 93% and 98.8%, respectively. Two patients in the older group and 14 patients in the younger group dropped out before SVR12 assessment. Although patients in the older group tended to have liver cirrhosis, 95.8% in the older group and 92% in the younger group achieved SVR12 in the ITT analysis (<jats:italic>P<\/jats:italic>\u2009=\u20090.404). In total, 48 (17.7%) patients experienced treatment-related AEs. Common AEs during treatment included pruritus, headache, and fatigue. The AEs were not significantly different between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared with younger patients, older patients showed similar virological response and tolerance to G\/P treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02284-z","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T16:04:12Z","timestamp":1651161852000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75\u00a0years or older"],"prefix":"10.1186","volume":"22","author":[{"given":"Yuri","family":"Komaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisayoshi","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Hasuike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsue","family":"Sueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Miike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shojiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Uto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Komada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kuroki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiharu","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Shigehira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Hirono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"2284_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41\u201352.","journal-title":"N Engl J Med"},{"key":"2284_CR2","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/jmv.24554","volume":"88","author":"LS Wang","year":"2016","unstructured":"Wang LS, D\u2019Souza LS, Jacobson IM. Hepatitis C-A clinical review. J Med Virol. 2016;88:1844\u201355.","journal-title":"J Med Virol"},{"key":"2284_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12072-015-9629-x","volume":"9","author":"H Benett","year":"2015","unstructured":"Benett H, Waser N, Johnston K, Kao JH, Lim YS, Duan ZP, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int. 2015;9:378\u201390.","journal-title":"Hepatol Int"},{"key":"2284_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000324525","volume":"54","author":"J Tanaka","year":"2011","unstructured":"Tanaka J, Koyama T, Mizui M, Uchida S, Katayama K, Matsuo J, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. 2011;54:185\u201395.","journal-title":"Intervirology"},{"key":"2284_CR5","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s12072-011-9312-9","volume":"6","author":"H Ebinuma","year":"2012","unstructured":"Ebinuma H, Saito H, Tada S, Nakamoto N, Ohishi T, Tsunematsu S, et al. Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score. Hepatol Int. 2012;6:744\u201352.","journal-title":"Hepatol Int"},{"key":"2284_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/hepr.12419","volume":"45","author":"I Sato","year":"2015","unstructured":"Sato I, Shimbo T, Kawasaki Y, Mizokami M, Masaki N. Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan: a retrospective study using the Japanese Interferon database. Hepatol Res. 2015;45:829\u201336.","journal-title":"Hepatol Res"},{"key":"2284_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/hepr.12898","volume":"47","author":"E Iio","year":"2017","unstructured":"Iio E, Shimada N, Takaguchi K, Senoh T, Eguchi Y, Atsukawa M, et al. Clinical evaluation of sofosbuvir\/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir\/asunaprevir therapy. Hepatol Res. 2017;47:1308\u201316.","journal-title":"Hepatol Res"},{"key":"2284_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/hepr.13242","volume":"49","author":"Y Takeuchi","year":"2019","unstructured":"Takeuchi Y, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, et al. Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. Hepatol Res. 2019;49:256\u201363.","journal-title":"Hepatol Res"},{"key":"2284_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/hep.28425","volume":"63","author":"S Saab","year":"2016","unstructured":"Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, et al. Safety and efficacy of ledipasvir\/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016;63:1112\u20139.","journal-title":"Hepatology"},{"key":"2284_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.dld.2017.04.012","volume":"49","author":"M Atsukawa","year":"2017","unstructured":"Atsukawa M, Tsubota A, Kondo C, Shimada N, Abe H, Kato K, et al. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Dig Liver Dis. 2017;49:1029\u201335.","journal-title":"Dig Liver Dis"},{"key":"2284_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40266-017-0515-1","volume":"35","author":"MA Jhaveri","year":"2018","unstructured":"Jhaveri MA, Manne V, Kowdley KV. Chronic hepatitis C in elderly patients: current evidence with direct-acting antivirals. Drugs Aging. 2018;35:117\u201322.","journal-title":"Drugs Aging"},{"key":"2284_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","volume":"53","author":"K Chayama","year":"2018","unstructured":"Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T, et al. Efficacy and safety of glecaprevir\/pibentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018;53:557\u201365.","journal-title":"J Gastroenterol"},{"key":"2284_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/hep.29510","volume":"67","author":"H Toyoda","year":"2018","unstructured":"Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018;67:505\u201313.","journal-title":"Hepatology"},{"key":"2284_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir\u2013pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354\u201369.","journal-title":"N Engl J Med"},{"key":"2284_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown","year":"2020","unstructured":"Brown RS, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, et al. Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72:441\u20139.","journal-title":"J Hepatol"},{"key":"2284_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","volume":"16","author":"T Asselah","year":"2018","unstructured":"Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, et al. Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16:417\u201326.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2284_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/hep.29541","volume":"67","author":"D Wyles","year":"2018","unstructured":"Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir\/Pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology. 2018;67:514\u201323.","journal-title":"Hepatology"},{"key":"2284_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","volume":"4","author":"T Asselah","year":"2019","unstructured":"Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:45\u201351.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2284_CR19","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Br\u00e4u N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448\u201355.","journal-title":"N Engl J Med"},{"key":"2284_CR20","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/liv.14320","volume":"40","author":"E Lawitz","year":"2020","unstructured":"Lawitz E, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, et al. Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int. 2020;40:1032\u201341.","journal-title":"Liver Int"},{"key":"2284_CR21","first-page":"129","volume":"65","author":"Y Karino","year":"2016","unstructured":"Karino Y. Innovation in hepatitis C treatment. J Jpn Assoc Rural Med. 2016;65:129\u201335.","journal-title":"J Jpn Assoc Rural Med"},{"key":"2284_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms19010023","volume":"19","author":"K Tsukiyama-Kohara","year":"2018","unstructured":"Tsukiyama-Kohara K, Kohara M. Hepatitis C virus: viral quasispecies and genotypes. Int J Mol Sci. 2018;19:23.","journal-title":"Int J Mol Sci"},{"key":"2284_CR23","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s00535-019-01569-7","volume":"54","author":"A Naganuma","year":"2019","unstructured":"Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, et al. Integrated analysis of 8-week glecaprevir\/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol. 2019;54:752\u201361.","journal-title":"J Gastroenterol"},{"key":"2284_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/hepr.13328","volume":"49","author":"E Ogawa","year":"2019","unstructured":"Ogawa E, Furusyo N, Nakamuta M, Nomura H, Satoh T, Takahashi K, et al. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real-world cohort study. Hepatol Res. 2019;49:617\u201326.","journal-title":"Hepatol Res"},{"key":"2284_CR25","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s00535-019-01575-9","volume":"54","author":"H Sezaki","year":"2019","unstructured":"Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, et al. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1\/2\/3 infections. J Gastroenterol. 2019;54:916\u201327.","journal-title":"J Gastroenterol"},{"key":"2284_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/liv.14295","volume":"40","author":"CH Liu","year":"2020","unstructured":"Liu CH, Liu CJ, Hung CC, Hsieh SM, Su TH, Sun HY, et al. Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection: real-world effectiveness and safety in Taiwan. Liver Int. 2020;40:758\u201368.","journal-title":"Liver Int"},{"key":"2284_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jvh.12828","volume":"25","author":"J Tanaka","year":"2018","unstructured":"Tanaka J, Akita T, Ohisa M, Sakamune K, Ko K, Uchida S, et al. Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat. 2018;25:363\u201372.","journal-title":"J Viral Hepat"},{"key":"2284_CR28","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1080\/14656566.2017.1400010","volume":"18","author":"CF Huang","year":"2017","unstructured":"Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother. 2017;18:1867\u201374.","journal-title":"Expert Opin Pharmacother"},{"key":"2284_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208506","volume":"14","author":"GR Foster","year":"2019","unstructured":"Foster GR, Asselah T, Kopecky-Bromberg S, Lei Y, Asatryan A, Trinh R, et al. Safety and efficacy of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS ONE. 2019;14: e0208506.","journal-title":"PLoS ONE"},{"key":"2284_CR30","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.3748\/wjg.v13.i41.5481","volume":"13","author":"O Akkaya","year":"2007","unstructured":"Akkaya O, Kiyici M, Yilmaz Y, Ulukaya E, Yerci O. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World J Gastroenterol. 2007;13:5481\u20135.","journal-title":"World J Gastroenterol"},{"key":"2284_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2185\/jrm.2020-004","volume":"15","author":"S Watanabe","year":"2020","unstructured":"Watanabe S, Morimoto N, Miura K, Murohisa T, Tahara T, Sato T, et al. Efficacy and safety of glecaprevir and pibrentasvir combination therapy in old-aged patients with chronic hepatitis C virus infection. J Rural Med. 2020;15:139\u201345.","journal-title":"J Rural Med"},{"key":"2284_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1089-3261(05)70158-6","volume":"5","author":"PJ Johnson","year":"2001","unstructured":"Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5:145\u201359.","journal-title":"Clin Liver Dis"},{"key":"2284_CR33","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/hep.27664","volume":"61","author":"MZ Molnar","year":"2015","unstructured":"Molnar MZ, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar-Zadeh K, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61:1495\u2013502.","journal-title":"Hepatology"},{"key":"2284_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237582","volume":"15","author":"HH Yen","year":"2020","unstructured":"Yen HH, Su PY, Zeng YH, Liu IL, Huang SP, Hsu YC, et al. Glecaprevir-pibrentasvir for chronic hepatitis C: comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLoS ONE. 2020;15: e0237582.","journal-title":"PLoS ONE"},{"key":"2284_CR35","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.29671","volume":"67","author":"F Poordad","year":"2018","unstructured":"Poordad F, Pol S, Asatryan A, Buti M, Shaw D, H\u00e9zode C, et al. Glecaprevir\/pibrentasuvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2018;67:1253\u201360.","journal-title":"Hepatology"},{"key":"2284_CR36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","volume":"53","author":"H Kumada","year":"2018","unstructured":"Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroentrol. 2018;53:566\u201375.","journal-title":"J Gastroentrol"},{"key":"2284_CR37","volume":"62","author":"P Krishman","year":"2018","unstructured":"Krishman P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, et al. Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62: e02217.","journal-title":"Antimicrob Agents Chemother"},{"key":"2284_CR38","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.jfma.2020.08.010","volume":"119","author":"WM Chen","year":"2020","unstructured":"Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, et al. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir\/pibrentasvir therapy. J Formos Med Assoc. 2020;119:1593\u2013600.","journal-title":"J Formos Med Assoc"},{"key":"2284_CR39","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/liv.14266","volume":"40","author":"A Brown","year":"2020","unstructured":"Brown A, Welzel TM, Conway B, Negro F, Br\u00e4u N, Grebely J, et al. Adherence to pan-genotypic glecaprevir\/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trials. Liver Int. 2020;40:778\u201386.","journal-title":"Liver Int"},{"key":"2284_CR40","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.14309\/ajg.0000000000001332","volume":"116","author":"PJ Zamor","year":"2021","unstructured":"Zamor PJ, Brown A, Dylla DE, Dillon JF, Luetkemeyer AF, Feld JJ, et al. High sustained virologic response rates of glecaprevir\/pibrentasvir in patients with dosing interruption or suboptimal adherence. Am J Gastroenterol. 2021;116:1896\u2013904.","journal-title":"Am J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02284-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02284-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02284-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T16:09:14Z","timestamp":1651162154000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02284-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2284"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02284-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of the University of Miyazaki. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all the study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest regarding the publication of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}